Clinical trial
A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4789, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.
NCT00917904 is registered in ClinicalTrials.gov with International Partnership for Microbicides, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4789, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.
- Lead sponsor
- International Partnership for Microbicides, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- September 30, 2010
- Enrollment
- 100 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.